ArticleFrontiers in endocrinology2026
Uric acid-based nutritional and inflammatory biomarkers for predicting cardiovascular-kidney-metabolic syndrome and mortality: a population-based study with external validation.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Uric acid-to-HDL cholesterol ratio (UHR) and uric acid-to-albumin ratio (UAR) are emerging composite biomarkers of nutrition and metabolic inflammation. This study investigates and compares their associations with advanced cardiovascular-kidney-metabolic (CKM) syndrome and all-cause mortality. Methods: This cross-sectional study included 17,833 adults from NHANES 2001-2020, with external validation in a clinical cohort of 300 hospitalized patients. Weighted logistic regression, restricted cubic spline (RCS), ROC curve, and Cox regression analyses were performed. Results: Both UHR and UAR were significantly elevated in patients with advanced CKM syndrome (both P < 0.001) and independently associated with increased CKM risk (UHR: OR = 1.07, 95%CI: 1.06-1.09; UAR: OR = 1.08, 95%CI: 1.06-1.10). Nonlinear associations were observed for both biomarkers, with inflection points at 9.46 for UHR and 15.79 for UAR (both P for nonlinear < 0.001). In ROC analysis, UAR slightly outperformed UHR in the NHANES cohort (AUC: 0.640 vs. 0.602), whereas UHR showed superior performance in the clinical cohort (AUC: 0.787 vs. 0.686). Both biomarkers remained independently associated with all-cause mortality after full adjustment. Conclusion: UHR and UAR are independently associated with advanced CKM syndrome and have complementary clinical utility. UAR may be preferred for early screening, whereas UHR may be better suited for CKM diagnosis and metabolic risk stratification. Their combined use may facilitate prognosis evaluation and mortality risk warning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.